Jeil PharmaceuticalLtd Balance Sheet Health
Financial Health criteria checks 3/6
Jeil PharmaceuticalLtd has a total shareholder equity of ₩170.8B and total debt of ₩64.8B, which brings its debt-to-equity ratio to 37.9%. Its total assets and total liabilities are ₩487.3B and ₩316.5B respectively. Jeil PharmaceuticalLtd's EBIT is ₩8.9B making its interest coverage ratio 1.8. It has cash and short-term investments of ₩35.7B.
Key information
37.9%
Debt to equity ratio
₩64.77b
Debt
| Interest coverage ratio | 1.8x |
| Cash | ₩35.66b |
| Equity | ₩170.83b |
| Total liabilities | ₩316.50b |
| Total assets | ₩487.33b |
Financial Position Analysis
Short Term Liabilities: A271980's short term assets (₩317.0B) exceed its short term liabilities (₩304.4B).
Long Term Liabilities: A271980's short term assets (₩317.0B) exceed its long term liabilities (₩12.1B).
Debt to Equity History and Analysis
Debt Level: A271980's net debt to equity ratio (17%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if A271980's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: A271980's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: A271980's interest payments on its debt are not well covered by EBIT (1.8x coverage).